- Home
- MIST vs CRDF Comparison
MIST vs CRDF Comparison
Compare MIST & CRDF Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- MIST
- CRDF
- Stock Information
- Founded
- MIST 2003
- CRDF 1999
- Country
- MIST Canada
- CRDF United States
- Employees
- MIST N/A
- CRDF N/A
- Industry
- MIST Biotechnology: Pharmaceutical Preparations
- CRDF Biotechnology: Biological Products (No Diagnostic Substances)
- Sector
- MIST Health Care
- CRDF Health Care
- Exchange
- MIST Nasdaq
- CRDF Nasdaq
- Market Cap
- MIST 163.2M
- CRDF 152.3M
- IPO Year
- MIST N/A
- CRDF N/A
- Fundamental
- Price
- MIST $1.80
- CRDF $2.24
- Analyst Decision
- MIST Strong Buy
- CRDF Strong Buy
- Analyst Count
- MIST 3
- CRDF 5
- Target Price
- MIST $6.33
- CRDF $11.10
- AVG Volume (30 Days)
- MIST 1.4M
- CRDF 762.1K
- Earning Date
- MIST 11-11-2025
- CRDF 10-29-2025
- Dividend Yield
- MIST N/A
- CRDF N/A
- EPS Growth
- MIST N/A
- CRDF N/A
- EPS
- MIST N/A
- CRDF N/A
- Revenue
- MIST N/A
- CRDF $545,000.00
- Revenue This Year
- MIST N/A
- CRDF N/A
- Revenue Next Year
- MIST N/A
- CRDF N/A
- P/E Ratio
- MIST N/A
- CRDF N/A
- Revenue Growth
- MIST N/A
- CRDF N/A
- 52 Week Low
- MIST $0.63
- CRDF $1.90
- 52 Week High
- MIST $2.75
- CRDF $5.64
- Technical
- Relative Strength Index (RSI)
- MIST 40.52
- CRDF 49.28
- Support Level
- MIST $1.76
- CRDF $2.20
- Resistance Level
- MIST $1.96
- CRDF $2.36
- Average True Range (ATR)
- MIST 0.09
- CRDF 0.10
- MACD
- MIST -0.02
- CRDF 0.00
- Stochastic Oscillator
- MIST 13.79
- CRDF 49.98
About MIST Milestone Pharmaceuticals Inc.
Milestone Pharmaceuticals Inc is a biopharmaceutical company dedicated to developing and commercializing etripamil for the treatment of cardiovascular medicines. Etripamil is a calcium channel blocker developed as a rapid-onset nasal spray to be administered by the patient to treat episodes of paroxysmal supraventricular tachycardia, or PSVT. The company has an ongoing Phase 2 clinical trial for patients with atrial fibrillation experiencing a rapid ventricular rate (AFib-RVR).
About CRDF Cardiff Oncology Inc.
Cardiff Oncology Inc is a clinical-stage biotechnology company leveraging PLK1 inhibition, a well-validated oncology drug target, to develop novel therapies across a range of cancers with the greatest unmet medical need. It is focusing on clinical programs in indications such as RAS-mutated metastatic colorectal cancer ("mCRC"), as well as in investigator-initiated trials in metastatic pancreatic ductal adenocarcinoma ("mPDAC"), small cell lung cancer ("SCLC"), and triple negative breast cancer ("TNBC"). Geographically, the company only operates in the United States.